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ABSTRACT
We previously found that mesenchymal stem cells (MSCs)
derived from human-induced pluripotent stem cells (iPSCs)
exerted immunomodulatory effects on Th2-mediated aller-
gic rhinitis in vitro. However, their contribution to the
asthma and allergic rhinitis in animal models remains
unclear. In this study, we developed a mouse model of oval-
bumin (OVA)-induced allergic inflammation in both the
upper and lower airways and evaluated the effects of the
systemic administration of human iPSC-MSCs and bone
marrow-derived MSCs (BM-MSCs) on allergic inflamma-
tion. Our results showed that treatments with both the
iPSC-MSCs and BM-MSCs before the challenge phase pro-
tected the animals from the majority of allergy-specific
pathological changes. This protection included an inhibition
of inflammatory cell infiltration and mucus production in
the lung, a reduction in eosinophil infiltration in the nose,
and a decrease in inflammatory cell infiltration in both the
bronchoalveolar and nasal lavage fluids. In addition, treat-
ment with iPSC-MSCs or BM-MSCs before the challenge
phase resulted in reduced serum levels of Th2 immunoglo-
bulins (e.g., IgE) and decreased levels of Th2 cytokines
including interleukin (IL)-4, IL-5, or IL-13 in the bron-
choalveolar and/or nasal lavage fluids. Similar therapeutic
effects were observed when the animals were pretreated
with human iPSC-MSCs before the sensitization phase.
These data suggest that iPSC-MSCs may be used as an al-
ternative strategy to adult MSCs in the treatment of asthma
and allergic rhinitis. Stem Cells 2012;30:2692–2699
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Mesenchymal stem cells (MSCs) are multipotent cells that
are capable of differentiating into three types of mesenchy-
mal cells: adipocytes, osteoblasts, and chondrocytes [1].
Increasing evidence in animal studies and in preliminary
clinical trials has demonstrated that MSCs not only possess
multipotent differentiation potential but also exhibit strong
immunomodulation potential via their interaction with T
lymphocytes, B lymphocytes, natural killer (NK) cells, and
dendritic cells (DC) [2–4]. Adult bone marrow-derived
MSCs (BM-MSCs) were initially reported and have been the
main source for the isolation of MSCs. However, there are
several potential limitations of using adult MSCs, including
their limited capacity to proliferate, the significant variability
in cell quality derived from different donors and a rapid loss
of their differentiation potential [5–7]. In addition, aging and
aging-related disorders significantly impair the survival and
differentiation potential of BM-MSCs, thus limiting their
therapeutic efficacy [8, 9].
We recently succeeded in inducing MSCs from human
induced pluripotent stem cell (iPSCs) [10]. iPSC-MSCs not
only express well-known adult BM-MSC markers and display
the potential for adipogenesis, osteogenesis, and chondrogene-
sis but also displayed a higher capacity for both proliferation
and telomerase activity. In addition, iPSC-MSCs were supe-
rior in the repair of tissue ischemia via paracrine and transdif-
ferentiation mechanisms compared with their adult BM-MSC
counterparts [10]. iPSC-MSCs have been demonstrated to
display significant inhibition of NK cell proliferation and
cytolytic function [11]. However, the anti-inflammatory or
immunomodulatory properties of iPSC-MSCs have not been
defined in vivo.
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Asthma and allergic rhinitis (AR) are chronic, reversible al-
lergic airway diseases that have become a significant global pub-
lic health concern [12]. According to the Global Initiative for
Asthma, approximately 300 million people suffer from asthma,
resulting in substantial medical and financial burdens [13, 14].
An increasing body of evidence indicates that the upper and
lower airways share common inflammatory mechanisms [15],
including eosinophilic inflammation in the subepithelial mucosa
and Th2 skewing of the immune response [16]. Adult MSCs
have been demonstrated to suppress allergic airway inflamma-
tory diseases, including asthma [17–20] and AR [21, 22], in ani-
mal models. We previously found that similar to BM-MSCs,
iPSC-MSCs significantly inhibited the levels of Th2 cytokines
including interleukin (IL)-4, IL-5, and IL-13 and promoted regu-
latory T cell responses after coculture with peripheral blood
mononuclear cells of AR patients [23]. The potential role of
iPSC-MSCs in attenuating allergic airway inflammation requires
further investigation in animal models. In this study, we devel-
oped a mouse model of allergic inflammation in both the upper
and lower airways, and the effects of the systemic administration
of human iPSC-MSCs compared with BM-MSCs on allergy-spe-
cific pathology and Th2 cytokines were evaluated.
MATERIALS AND METHODS
Animals
Female BALB/c mice (4–6 weeks of age) were purchased from
Experimental Animal Center, Sun Yat-sen University (Guangzhou,
People’s Republic of China) and housed under specific pathogen-
free conditions. All procedures were performed according to proto-
cols approved by the Institutional Animal Care and Use Commit-
tee, Sun Yat-sen University (No. IACUC 20110228002).
Preparation of Human iPSC-MSCs and BM-MSCs
and Flow Cytometry Analysis of Surface Marker
Expression
Two clones of iPSC-MSCs, iMR90-iPSC-MSCs 10 [10] and N1-
iPSC-MSCs [24], were used in this study. iMR90-iPSC-MSCs 10
were generated from iPSC-iMR90-5 (WiCell Research Institute,
Madison, WI, http://www.wicell.org) [10]. The N1-iPSC-MSC
clone was prepared from iPSCs reprogrammed from human fibro-
blast cells as shown in our previous study [24]. The iPSCs were
differentiated into MSCs according to the protocol previously
described [25]. Briefly, MSCs were purified by sorting for
CD105þ/CD24 cells and were maintained in medium contain-
ing 90% knockout Dulbecco’s modified Eagle’s medium (Gibco,
Invitrogen Corporation, Carlsbad, CA, http://www.invitrogen.com)
supplemented with 10% serum replacement medium (Gibco) and
basic fibroblast growth factor (10 ng/ml, Gibco). MSC identity
was verified by surface marker expression of CD24, CD34, CD31,
CD44, CD73, CD29, CD105, and CD166 using phycoerythrin
(PE)- or fluorescein isothiocyanate (FITC)-conjugated antibodies
(BD Biosciences, San Jose, NJ, http://www.bdbiosciences.com).
The iPSC-MSCs were morphologically highly similar to BM-
MSCs and had similar surface antigen expression, including
expression of CD44, CD49a and e, CD73, CD105, and CD166
and lack of expression of CD45, CD34, and CD133. Furthermore,
the iPSC-MSCs were identified to have the capacity to differenti-
ate into osteoblasts, adipocytes, and chondroblasts. Human BM-
MSCs were purchased commercially and served as the control
cells (Cambrex BioScience, Rockland, ME, http://www.cambrex.-
com; catalog number PT-2501). We used the MSCs at the fourth
through the sixth passages for transplantation.
Mouse Model of Allergic Airways Inflammation
A mouse model of allergic airways inflammation was induced as
previously reported with minor modification [26]. Briefly, mice
were sensitized by intraperitoneal injection of 40 lg of ovalbumin
(OVA, grade V, Sigma, St. Louis, MO, http://www.sigmaaldrich.-
com) in 2 mg of aluminum hydroxide (Sigma) in 200 ll pyrogen-
free phosphate-buffered saline (PBS) on days 1, 3, 5, 7, 9, 11,
and 13, as shown in Figure 1. From days 21 to 27, mice were
challenged daily with aerosolized 5% OVA in a plexiglass cham-
ber and through an air-compressing nebulizer (403A, yuyue,
Danyang, Jiangsu, People’s Republic of China, http://
www.yuyue.com.cn) for 30 minutes. Subsequently, mice were
intranasally infused with 20 ll OVA (40 mg/ml). The animals
were sacrificed via cervical dislocation at day 29.
Human iPSC-MSCs or BM-MSCs Transplantation
Two clones of human iPSC-MSCs, iMR90-iPSC-MSCs and N1-
iPSC-MSCs or human BM-MSCs were suspended in sterile PBS at
a density of 5  106 cells per ml. On day 0 or 20, 0.2 ml of cells
or of the sterile PBS was injected via the tail vein (Fig. 1). Mice
were divided into seven groups: (A) PBS/PBS/PBS mice that were
sensitized and challenged with PBS were then injected with PBS
on day 20 (n ¼ 5); (B) naı¨ve/naı¨ve/iPSC-MSCs mice that were na-
ı¨ve mice treated with iPSC-MSCs (n ¼ 5); (C) OVA/OVA/PBS
mice that were sensitized and challenged with OVA, then treated
with PBS on day 20, (n ¼ 5); (D) OVA/OVA/iMR90-iPSC-MSC
mice that were sensitized and challenged with OVA and then
treated with iMR90-iPSC-MSCs (n ¼ 6); (E) OVA/OVA/N1-
iPSC-MSC mice that were sensitized and challenged with OVA
and then treated with N1-iPSC-MSCs on day 20 (n ¼ 5); (F)
OVA/OVA/BM-MSC mice that were sensitized and challenged
with OVA and then treated with BM-MSCs (n ¼ 4); (G) iPSC-
MSC/OVA/OVA mice that were treated with iMR90-iPSC-MSCs
on day 0, and then sensitized, challenged with OVA (n ¼ 5).
Evaluation of Nasal Symptoms
The frequency of sneezing and nose rubbing that occurred in the
10-minute time period after the last challenge was determined as
Figure 1. Schematic diagram showing the mouse model of allergic
airway inflammation. Mice were sensitized on days 1, 3, 5, 7, 9, 11,
and 13 by intraperitoneal injection of OVA with aluminum hydroxide.
From days 21 to 27, the mice were challenged with aerosolized 5%
OVA in a plexiglass chamber for 30 minutes and subsequently intra-
nasally exposed to 20 ll of OVA (40 mg/ml) each day. Purified
iMR90-iPSC-MSCs, N1-iPSC-MSCs, or BM-MSCs (1  106) were
injected via the tail vein on day 20. Moreover, human iMR90-iPSC-
MSCs (1  106) were preinjected via the tail vein on day 0. Samples
were collected on day 29. The mice were divided into seven different
groups in accordance with the different treatments of sensitization,
challenge and injection or preinjection, sensitization and challenge.
Abbreviations: BM-MSC, bone marrow-derived mesenchymal stem
cell; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal
stem cell; OVA, ovalbumin; PBS, phosphate-buffered saline.
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previously reported [27]. Mice were subjected to a single-blind
observation by examiners who had no knowledge of the experi-
mental groups.
Evaluation of the Inflammatory Cells and Cytokines
in the Nasal and Bronchoalveolar Lavage Fluids
At 29 days, the nasal lavage fluid (NALF) and bronchoalveolar
lavage fluid (BALF) were collected. Briefly, the upper level of
the trachea was ligated and a 22-gauge catheter was inserted into
the nasopharynx. The nasal cavities were gently perfused with 1
ml cold PBS, and NALF was collected from the nose. BALF was
obtained after lavage with 1 ml of cold PBS via a 20-gauge nee-
dle inserted through the upper part of the trachea. After centrifu-
gation, the cells present within the NALF and BALF were
counted using a hemocytometer and then cytospun onto glass
slides and stained with Diff-Quick (Baso Diagnostics Inc.,
ZhuHai, Guangdong, People’s Republic of China; www.baso-
diagnostics.com). A total of 300 cells per slide were evaluated
for eosinophils, macrophages, neutrophils, and lymphocytes at
400 magnification, as previously reported [17]. The levels of
IL-4, IL-5, IL-13, and interferon (IFN)-c in the supernatants were
measured using sandwich enzyme-linked immuno sorbent assay
(ELISA) analysis following the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, http://www. rndsystems.com).
Lung and Nasal Histology and Inflammation Scoring
Lung and nasal tissues were removed after the lavage and fixed
in 10% neutral formalin for 36 hours. The lungs were then
embedded in paraffin, and nasal tissues were embedded in paraf-
fin after being decalcified. Nasal tissues were prepared in a coro-
nal plane at a distance of 5 mm from the nasal vestibule, and
lung sections were prepared at a thickness of 4 lm. The sections
were then stained with hematoxylin and eosin (H&E) for nasal
tissues, and for lung tissues they were stained with both H&E
and periodic acid–Schiff (PAS). The number of eosinophils was
evaluated in the submucosal area of the whole nasal septum by
microscopy (400 magnification). Goblet cell (PAS positive cell)
counts and inflammation score in the lungs were performed in a
blinded fashion using a reproducible scoring system, as previ-
ously described [28, 29]. Briefly, for quantifying the lung inflam-
mation, five sections across the main bronchus of each animal
were randomly selected and given scores ranging from 0 to 3
based on the level of peribronchial inflammation and perivascular
inflammation. The values were given according to the following
inflammatory parameters: 0 when no inflammation was detecta-
ble; 1 for occasional cuffing with inflammatory cells; 2 for most
bronchi or vessels surrounded by a thin layer (1–5 cells) of
inflammatory cells; and 3 when most bronchi or vessels were sur-
rounded by a thick layer (more than five cells) of inflammatory
cells. For quantifying the goblet cell hyperplasia, the percentage
of PAS-positive cells in epithelial areas was examined from 8 to
10 tissue sections per mouse.
Measurement of Serum Immunoglobulin Response
The levels of OVA-specific IgE and IgG1 in serum were assayed
using commercial ELISA kits (Shibayagi, Shibukawa, Gunma, Ja-
pan) following the manufacturer’s instructions.
Statistical Analysis
The experimental data were expressed as the mean 6 SEM. Sta-
tistical analysis was performed using a one-way analysis of var-
iance followed by a Student-Newman-Keuls test for multiple
comparisons of the data with Gaussian distribution. A Kruskal–
Wallis rank sum test followed by a Mann–Whitney U test was
performed for two-group comparisons of the data with abnormal
distribution. Statistical analysis was performed using GraphPad
Prism 5 software (San Diego, CA), and p < .05 was considered
statistically significant.
RESULTS
Systemic Administration of Human iPSC-MSCs
Suppresses Allergic Nasal Symptoms
To determine whether human iPSC-MSCs have immunomo-
dulatory functions in allergic inflammation, a mouse model of
asthma and AR was developed. First, we investigated whether
the administration of human iPSC-MSCs inhibited the occur-
rence of nasal symptoms. The frequency of sneezing and
nasal rubbing in 10 minutes after the final challenge in the
OVA/OVA/PBS group was significantly higher than that in
the PBS group (p < .05) (Supporting Information Fig. 1A,
1B). However, treatment with iMR90-iPSC-MSCs (p < .05),
N1-iPSC-MSCs (p < .01), and BM-MSCs (p < .05) before
the challenge phase significantly reduced sneezing and nasal
rubbing. The N1-iPSC-MSCs had a better inhibitory effect on
sneezing when compared with the iMR90-iPSC-MSCs (p <
.01). Interestingly, we found that the treatment with iPSC-
MSCs before the sensitization phase had similar effects on
reducing nasal rubbing and sneezing (p < .01). There was no
difference in the nasal symptoms between naı¨ve/naı¨ve/iPSC-
MSC mice and PBS-challenged mice. These data suggest that
both human iPSC-MSCs and BM-MSCs have a comparable
suppressive effect on allergic nasal symptoms.
Systemic Administration of Human iPSC-MSCs
Reduces OVA-Induced Upper and Lower Airway
Inflammation
We qualitatively and quantitatively evaluated the effect of
human iPSC-MSC treatment before the challenge phase on
the histopathology of the lung and nose. OVA/OVA/PBS
mice exhibited obvious inflammatory cell infiltration (p <
.001) in the peribronchial tissue, goblet cell hyperplasia as
shown by PAS-positive cells in the bronchi (p < .001) and
eosinophilic infiltration in the nasal submucosa (p < .01)
(Fig. 2A–2D). Treatment with both clones of human iPSC-
MSCs resulted in a significant decrease in lower airway
inflammation (p < .001), goblet cell hyperplasia (p < .01),
and upper airway inflammation (p < .01). Similar inhibitory
effects were detected in the BM-MSC-treated mice (p < .001
for the inflammation score, p < .01 for the PAS-positive cells
in the lungs, and p < .05 for eosinophils in the nasal septum)
(Fig. 2A–2D). These data suggested that iPSC-MSCs had a
comparable effect in attenuating allergic airway inflammation
as human BM-MSCs. Moreover, we examined the effects of
pretreating the mice with human iPSC-MSCs before the sensi-
tization phase in our model. As illustrated in Figure 2, we
observed a significant inhibition of inflammatory cell infiltra-
tion (p < .001) and goblet cell hyperplasia in the lungs
(p < .05) as well as eosinophilic infiltration in the nose (p <
.01). These data indicate that human iPSC-MSCs have the
ability to inhibit the development of allergic inflammation
during both the sensitization and challenge phases of the
disease. In our study, no allergen-driven airway inflammation
was found in naı¨ve/naı¨ve/iPSC-MSC mice. Although only a
small number of transplanted iPSC-MSCs remained detectable
in lung and nose tissues in iPSC-MSC-treated mice with
OVA-induced allergic inflammation after transplantation, no
transplanted iPSC-MSCs were detected in naı¨ve/naı¨ve/iPSC-
MSC mice after transplantation (data not shown).
We next examined the effect of human iPSC-MSCs on
the OVA-induced inflammatory cell profiles in the BALF and
NALF. The numbers of total and differential subsets of
inflammatory cells increased in the BALF and in the NALF
of OVA/OVA/PBS mice with the exception of macrophages
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(all p < .01, Fig. 3). However, treatment with both iMR90-
iPSC-MSCs (p < .01) and N1-iPSC-MSCs (p < .05) 1 day
before challenge phase significantly decreased the total num-
ber of inflammatory cells in the BALF. Differential staining
demonstrated a decrease in eosinophils, macrophages, neutro-
phils, and lymphocytes upon two clone treatment but not
macrophages upon treatment with N1-iPSC-MSCs (p < .05 or
p < .01) (Fig. 3A, 3C). As for the NALF, similar effects
were observed for total inflammatory cells and eosinophils
upon treatment with both clones of iPSC-MSCs and for lym-
phocytes upon N1-iPSC-MSC treatment (p < .05 or p < .01,
Fig. 3B, 3D). Treatment with BM-MSCs demonstrated the
same effects on the total and the differential subsets of
inflammatory cells in the BALF (all p < .05) and eosinophils
in the NALF (p < .05). Interestingly, we also observed a sig-
nificant decrease in eosinophils in both the BALF and NALF
of animals that were pretreated with iPSC-MSCs before the
sensitization phase (both p < .01). Treatment of naı¨ve mice
with human iPSC-MSCs alone did not affect the cell profiles
of either the NALF or BALF compared with the PBS/PBS/
PBS mice (p > .05). Taken together, our findings indicated
that iPSC-MSCs were capable of attenuating the pathology
observed in both the lung and nose in this mouse model of
OVA-induced airway disease. Additionally, the iPSC-MSCs
exerted their effect both on the sensitization phase and on the
challenge phase.
Figure 2. Administration of human iPSC-MSCs attenuated OVA-induced airway inflammation in the lung and nose. (A): Representative photo-
micrographs of H & E- and PAS-stained lung sections and H & E-stained nose sections from each group. Note the significant increase in inflam-
matory infiltrates (lung H&E, shown by arrows) and mucus accumulation at the luminal surface of the bronchi (lung PAS staining, shown by
arrows) and eosinophil infiltrates in the nose (nose H&E, shown by arrows) in the OVA/OVA/PBS group. Original magnification 200 (lung) and
400 (nose). Statistical analysis for inflammation score (B) and mucus hypersecretion as quantified by PAS scores (C) in the lungs, and eosino-
philic infiltration in the nasal submucosa (D). Mean 6 SEM. *, p < .05; **, p < .01; ***, p < .001 by Kruskal–Wallis rank sum test followed by
the Mann–Whitney U test for two-group comparisons. Abbreviations: BM-MSC, bome marrow-derived mesenchymal stem cell; H&E, hematoxylin
and eosin; iPSC-MSC, induced pluripotent stem cell; nd, not detectable; ns, no significance; OVA, ovalbumin; PAS, periodic acid–Schiff; PBS,
phosphate-buffered saline.
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Systemic Administration of Human iPSC-MSCs
Decreases Circulating Levels of OVA-Specific IgE
OVA sensitization and challenge is known to increase
Th2-specific immunoglobulin concentrations in the sera. We
confirmed a significant elevation in the serum levels of OVA-
specific IgE and OVA-specific IgG1 (both p < .01) in our
allergic model (Fig. 4). Systemic administration of both
iMR90-iPSC-MSCs (p < .01) and N1-iPSC-MSCs (p < .05)
1 day before the challenge resulted in a significant decrease
in serum OVA-specific IgE, but not IgG1 levels. Interestingly,
we observed different levels of IgE between the iMR90-iPSC-
MSC and N1-iPSC-MSC treatment (p < .05), suggesting that
there is a different degree of allergic IgE inhibition by the dif-
ferent iPSC-MSC clones. Administration of BM-MSCs signifi-
cantly decreased OVA-induced IgE and IgG1 serum levels
(both p < .05), a result that was consistent with the decreased
levels of specific IgE and IgG1 observed upon treatment with
BM-MSCs in a mouse model of ragweed-induced asthma
[18]. Moreover, we observed that the IgG1 levels were lower
with the BM-MSC treatment when compared with both clones
of iPSC-MSCs after OVA challenge (p < .05), suggesting
their different abilities to regulate immunoglobulin production
in allergic disease. Interestingly, the treatment of iPSC-MSCs
before the sensitization significantly decreased OVA-specific
IgE levels (p < .05). Treatment with human iPSC-MSCs in
naı¨ve mice did not affect the levels of either OVA-specific
IgE or IgG1. Here, IgE represents the Th2 immune response,
and it was significantly decreased by the treatments with the
iPSC-MSC clones before sensitization and before challenge,
indicating that the i.v. injection of iPSC-MSCs was responsi-
ble for downregulating the Th2 response in the allergic airway
model.
Systemic Administration of Human iPSC-MSCs
Alters Cytokine Levels in Both the BALF and
NALF
We next determined the levels of the T helper cell-derived cyto-
kines that were present in the BALF and NALF after adminis-
tration of human iPSC-MSCs and BM-MSCs (Fig. 5). OVA-
challenged mice showed increased levels of IL-4, IL-5, and IL-
13 in the BALF (all p < .05), and IL-4 (p < .001) and IL-5 in
the NALF (p < .05). These cytokines are characteristic of Th2
allergic inflammation. In contrast, treatment with human
iMR90-iPSC-MSCs resulted in a significant decrease in IL-4,
IL-5, and IL-13 (all p < .05) in the BALF, and treatment with
N1-iPSC-MSCs resulted in a significant decrease in IL-5 and
IL-13 in the BALF and IL-4 in the NALF (all p < .05). Treat-
ment with BM-MSCs not only showed a similar effect in
decreasing IL-4, IL-5, and IL-13 in the BALF (all p < .05) but
also reduced the levels of IL-4 (p < .001) and IL-5 (p < .05) in
the NALF. Furthermore, pretreatment with iPSC-MSCs before
the sensitization phase significantly reduced the levels of IL-4,
IL-5, and IL-13 in the BALF and IL-5 in the NALF (all p <
.05). High levels of IFN-c were observed in both the BALF and
Figure 3. Systemic treatment with human iPSC-MSCs or BM-MSCs inhibits inflammatory cell infiltration in the BALF and NALF. Representa-
tive diff-quick staining of the inflammatory cells present in the BALF (A) and NALF (B). Inflammatory cell counts in the BALF (C) and NALF
(D). Mean 6 SEM. *, p < .05; **, p < .01 as conducted using a one-way analysis of variance and the Student-Newman-Keuls method for post
hoc analysis for the total inflammatory cells, macrophages, and lymphocytes in the NALF, and using the Kruskal–Wallis rank sum test followed
by the Mann–Whitney U test for two-group comparisons for the other parameters. Abbreviations: BALF, bronchoalveolar lavage fluid; BM-MSC,
bone marrow-derived mesenchymal stem cell; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal stem cell; NALF, nasal lavage
fluid; ns, no significance; OVA, ovalbumin; PBS, phosphate-buffered saline.
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NALF in OVA/OVA/PBS mice (both p < .05, Fig. 5), and
there were no differences after treatment with both clones of
iPSC-MSCs. Treatment with BM-MSCs increased the levels of
IFN-c in the BALF when compared with OVA/OVA/PBS mice
and three group mice treated with the iPSC-MSC clones (p <
.05 or p < .01). These data suggest that iPSC-MSC treatment
reduced the levels of Th2 cytokines in allergic inflammation,
especially in the BALF. The differences between the effect of
iPSC-MSCs and BM-MSCs on the cytokine levels in the NALF
may be due to different MSC properties and different secretome
profiles of MSCs derived from iPSCs or bone marrow.
DISCUSSION
The immunomodulatory function of MSCs makes them prom-
ising candidates for allergic disease therapy. MSCs generated
from iPSCs are morphologically and functionally similar to
BM-MSCs [10]. Because of the limited proliferative capacity
and the rapid loss of differentiation potential of adult MSCs
[5–7], iPSC-MSCs with an unlimited resource might provide
an alternative source of stem cells for therapeutic use.
In this study, we induced allergic inflammation in both the
upper and lower airways of mice. Similar to BM-MSCs, we
demonstrated that human iPSC-MSCs significantly inhibited
nasal eosinophilia and lung pathology, decreased the levels of
Th2 cytokines in the NALF and BALF and decreased IgE lev-
els in the serum. These data are consistent with previous stud-
ies that MSCs from BM or adipose tissues attenuated allergic
responses in asthma and AR [18–21, 30, 31]. More impor-
tantly, the above findings were confirmed using two different
clones of human iPSC-MSCs, indicating their stable capability
to regulate the immune response during allergic inflammation.
Some small differences were found in the effect between the
two iPSC-MSCs clones, such as macrophage numbers and IL-4
levels in the BALF and lymphocyte numbers in the NALF.
These differences may be due to differences in the cell sources
of iPSCs, the process of induction, the culture conditions, and
even the passages. Considering that the immunosuppressive
function of iPSC-MSCs is maintained during multiple passages
without any senescence in contrast to BM-MSCs [2, 11], it is
Figure 4. Systemic administration of human iPSC-MSCs or BM-MSCs decreases the serum levels of OVA-specific IgE. OVA-specific IgE (A)
and IgG1 (B) levels in the sera of mice following the different treatments. The data are expressed as the mean 6 SEM. *, p < .05; **, p < .01
by the Kruskal–Wallis rank sum test followed by the Mann–Whitney U test for two-group comparisons. Abbreviations: BM-MSC, bone marrow-
derived mesenchymal stem cell; iPSC-MSC, induced pluripotent stem cell-derived mesenchymal stem cell; ns, no significance; OVA, ovalbumin;
PBS, phosphate-buffered saline.
Figure 5. Systemic administration of human iPSC-MSCs inhibits the production of inflammatory cytokines in the BALF and NALF. The cyto-
kine levels in the BALF and NALF were measured using enzyme-linked immunosorbent assay. The data are expressed as the mean 6 SEM. *,
p < .05; **, p < .01; ***, p < .001 as measured by a one-way analysis of variance and the Student-Newman-Keuls method for post hoc analysis
IL-13 in the BALF and IL-4 in the NALF, and by the Kruskal–Wallis rank sum test followed by the Mann-Whitney U test for two-group com-
parisons for the other parameters. Abbreviations: BALF, bronchoalveolar lavage fluid; IFN, interferon; IL: interleukin; iPSC, induced pluripotent
stem cell; MSC, mesenchymal stem cell; NALF: nasal lavage fluid; OVA, ovalbumin; PBS, phosphate-buffered saline.
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plausible that iPSC-MSCs may offer a long-lasting, more
efficient immunoregulatory function to allergic disease than
BM-MSCs. To our knowledge, this is the first study to investi-
gate the potential role of iPSC-MSCs in the modulation of the
allergic response in an animal model.
Interestingly, we found that pretreatment with iPSC-MSCs
before the sensitization phase exhibited similar, if sometimes
weaker, effects on allergic inflammation when compared with
iPSC-MSC administration before the challenge phase. These
data are consistent with a previous study in which treatment
with human gingiva-derived MSCs before both the sensitiza-
tion and challenge phases attenuated contact hypersensitivity
[32]. In the development of allergic disorders, DC and
allergy-specific T cells are involved in the sensitization phase,
and allergy-specific T cells and mast cells are involved in the
challenge phase [16]. BM-MSCs were demonstrated to affect
the functions of DCs [33], T cells [34], and mast cells [35].
Similarly, we have found that human iPSC-MSCs inhibit the
proliferation of T lymphocytes and modulate T-cell pheno-
types in AR [23]. Our findings indicate that iPSC-MSCs may
work on different cells in different phases of allergic inflam-
mation, suggesting a broad immunomodulation by iPSC-
MSCs. It allows the iPSC-MSCs to rectify the imbalance of
the immune responses in different environments.
We found some differences in the effect of iPSC-MSCs and
BM-MSCs on the serum levels of IgG1, the levels of IL-4 and
IL-5 in the NALF, and the IFN-c levels in the BALF. Similar
to our study, BM-MSCs were demonstrated to increase IFN-c
levels [17, 21] and decrease IgG1 levels [18] in an asthma
model. These different effects may be related to the different
properties and different secretome profiles of MSCs derived
from adult tissues or pluripotent stem cells. iPSC-MSCs dis-
played different proliferative capacity and telomerase activity
when compared with BM-MSCs [10]. Furthermore, using a
cytokine antibody array, we found that conditioned medium
from human embryonic stem cell (ESC)-MSCs and BM-MSCs
had many common characteristics but also some distinct differ-
ences in paracrine factor profiling, such as in human originated
angiogenin [36]. We also demonstrated a difference in the
secretome profiles between iPSC-MSCs and BM-MSCs against
anthracclines-induced cardiomyopathy (Q. Lian et al., manu-
script submitted for publication). The differential paracrine fac-
tor profile between iPSC-MSCs and BM-MSCs might account
for some of the differences between their effects on the levels
of cytokines and IgG1 in response to OVA-induced allergy.
There are some limitations of this study. An important
limitation is that the study of immune rejection after human
iPSC-MSCs were transplanted into immunocompetent mice is
lacking. Nevertheless, studies of human MSCs from adult
tissues in immunocompetent animals without using immuno-
suppressants have been performed, and many studies have
demonstrated that human MSCs have therapeutic potential in
immunocompetent rodent models of immune diseases, such as
asthma [19, 20], AR [22], contact hypersensitivity [32], and
systemic lupus erythematosus [37, 38]. Similarly, we demon-
strated the therapeutic activity of human iPSC-MSCs to aller-
gic airway inflammation in immunocompetent mice. We
acknowledge the possibility that immune rejection could
occur in our study. It should be further studied in immnuo-
compromised mice in the future. In addition, it should none-
theless be noted that the immunomodulatory properties of
human iPSC-MSCs in the attenuation of allergic inflammation
would be desirable, there are challenges to overcome prior to
their clinical application. Although we and other labs have
not observed the teratogenic effects of human ESC/iPSC-
MSCs in animal studies [36, 39], the safety concerns on
genomic instability of iPSCs and ESCs need to be evaluated
carefully before clinical translation [40, 41].
CONCLUSION
In summary, we demonstrated that similar to BM-MSCs, the
administration of iPSC-MSCs significantly suppressed the pa-
thology and permitted a re-balance in the immune response in
a mouse model of allergic inflammation in both the upper and
lower airways. Pluripotent stem cells potentially offer an
unlimited source for functional and mass MSC generation.
Our data provide preliminary evidence that iPSC-MSCs may
be used as a novel alternative to adult MSCs in the treatment
of allergic airway diseases.
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